Document is current

Article History

Accepted: 8 April 2025

First Online: 29 April 2025

Declarations

:

: This study was funded by the Food and Drug Administration, Ministry of Public Health, Thailand, and Thailand Science Research and Innovation. This paper represents the views of the authors. This study was conducted at the request of the National List of Essential Medicines (NLEM). This manuscript is a part of the project “Economic evaluation of imiglucerase and velaglucerase for the treatment of type 1 and 3b Gaucher disease,” which was used to support the policy-making process under the Subcommittee for the Development of the NLEM in Thailand through the Health Economic Working Group (HEWG); however, the HEWG is not responsible for the study findings and the dissemination of the findings.

: The authors declare no conflicts of interest.

: The individual patient data from six participating hospitals cannot be made publicly available for privacy and confidentiality reasons. The economic model is fully replicable from the information reported in this paper.

: This research study received ethical approval from the Central Research Ethics Committee (CREC) of Thailand on 7 September 2023, with certificate no. CREC075/2023.

: Informed consent was obtained from all patients and/or their caregivers prior to their participation in the study.

: Not applicable.

: The executable model is available from the authors upon request.

: All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this article and have approved its publication. All authors contributed to the conception and design of the study. D.W., T.T., K.W., A.S., P.C., K.S., and C.T. collected patient data from six participating hospitals. W.R., T.A., and W.I. analyzed the input parameters. W.R. developed the model, reviewed input parameters, and conducted the economic evaluation. W.R. and Y.T. prepared the manuscript. All authors reviewed and approved the final version.